Brain tumours are a diverse group of neoplasms that continue to present a formidable challenge in our attempt to achieve curable intervention. Our conceptual framework of human brain cancer has been redrawn in the current decade. There is a gathering acceptance that brain tumour formation is a phenotypic outcome of dysregulated neurogenesis, with tumours viewed as abnormally differentiated neural tissue. In relation, there is accumulating evidence that brain tumours, similar to leukaemia and many solid tumours, are organized as a developmental hierarchy which is maintained by a small fraction of cells endowed with many shared properties of tissue stem cells.
Introduction

Characteristics of intracranial neoplasms
Of all solid cancers, brain tumours have the poorest survival and highest morbidity rates. Although frequently considered collectively, brain tumours represent a diverse range of tumour types affecting both children and adults. Tumours of the brain account for less than 2% of all malignancies, yet now approach leukaemia as the leading cause of cancer-related death in children and the fourth leading cause in adults [1] . The diversity of brain tumour type is a reflection of the histological complexity of the central nervous system (CNS) and can present with glial or neuronal phenotypes or a mixture of cell types.
Medulloblastoma and supratentorial primitive neuroectodermal tumours (sPNET) are World Health Organisation (WHO) grade IV embryonal tumours, resulting from the transformation of primitive neuroectodermal cells. The medulloblastoma is a malignant and invasive tumour with a relatively poor prognosis and represents the most common malignant brain tumour in children. It is predominately neuronal in nature and typically located in the cerebellum. In contrast the rarer sPNETs are more commonly found in the cerebral hemispheres and consist of poorly differentiated neuroepithelial cells which confer poor prognosis, especially in children. Despite both being classified as Grade IV tumours, sPNETs have a significantly worse prognosis [2] .
Also classified as a grade IV tumour by the WHO, glioblastoma multiforme (GBM) represents the most malignant and aggressive form of glioma, arising in the subcortical white matter as either a primary neoplasm, or from the malignant progression of a low grade glioma [3] . Typically seen in adults, prognosis is
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extremely poor as the diffuse distribution throughout the brain makes surgical resection difficult [4] .
Ependymoma are typically classified as glial tumours, however it is currently debated as to whether ependymoma may actually reflect a separate entity. Composed of neoplastic ependymal cells, the ependymoma is usually located along the ventricular system of the paediatric or adolescent brain whereas spinal sites are more commonly seen in adults. Prognosis is varied and is dependent on surgical resection [5, 6] .
Although an understanding of human brain cancer pathogenesis has increased in recent decades, insufficient knowledge of the molecular, genetic and cellular alterations and mechanisms is at the root of treatment failure and relatively limited diagnostic and prognostic capabilities. As a result, bio-centred and target-specific brain tumour therapy has not yet been forthcoming.
Neuro-developmental biology
The CNS is a highly complex structure which develops from a restricted number of extensively plastic cells that proliferate and acquire regional identities in space and time to produce a diverse repertoire of cell types. Collectively, these cells are defined as neural stem cells (NSCs) on the basis of their potential to differentiate into mature neurons and glia (astrocytes and oligodendrocytes) and their ability to self-renew in vitro. This operational definition does not however, necessarily reflect the function of NSCs in vivo and it remains uncertain whether the cell type(s)
exhibiting 'stemness' in vitro faithfully represents the cell exhibiting 'stemness' in vivo.
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Mammalian developmental neuro-biology now entertains an integrated view of NSCs whereby neuroepithelial cells comprising the neural tube of the developing embryo, give rise first to radial glia, which then transform into astrocyte-like adult multipotent stem cells or directly into mature ependymal cells lining the walls of the lateral ventricles, the latter of which are post-mitotic in the adult brain [7] . Radial glia arise from neuroepithelial cells throughout the primitive CNS at the beginning of neurogenesis and represent the predominant neuronal progenitor [8] . These cells characteristically display a radial morphology and a mixed primitive cell/glial immunophenotype. In mammals, radial glial cells disappear from the brain soon after birth, with a closely-related astrocyte-like cell taking the role as NSC thereafter. The belief that the genesis of new CNS cells is a rare event in the adult mammalian brain was established dogma until recently. Two constitutively active germinative layers are now known to reside in the adult brain: the subventricular zone (SVZ) associated with the anterior part of the forebrain lateral ventricles and the subgranular zone (SGZ)
within the hippocampus, corresponding to the inner layer of the dentate gyrus [9] [10] [11] .
New neurons and glia continue to be generated within these restricted regions of the adult mammalian brain [12] . Evidence that neurogenesis persists in the CNS of the adult mammalian brain (albeit in restricted domains) has changed our perception of the cell of origin with respect to neural neoplastic transformation [13, 14] .
Telomere and telomerase status during normal and dysregulated neurogenesis
In virtually all types of malignant cells, unlimited replicative potential is conferred in considerable part, by the maintenance of telomere length above a critical minimum threshold. Telomeres (derived from the Greek telos, meaning end and meros, a component) are a complex of guanine-rich repeat sequences and associated
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proteins that form a loop structure which caps all eukaryotic chromosome termini [15] and prevents chromosomes from improper recombination, nuclease degradation and end fusions, thereby contributing to genomic stability. Due to incomplete replication of lagging-strand synthesis at each mitotic division ('end-replication problem') [16] , telomeres progressively shorten, a phenomenon that provides a molecular basis of cellular ageing and hints at a primitive tumour-suppressor mechanism [17] . In germ cells and cancer cells, unlimited proliferative capacity is achieved through the addition of telomeric repeats by the telomerase holoenzyme. Telomerase is a ribonucleoprotein consisting of an RNA subunit (TR) which provides an intrinsic template for the synthesis of de novo telomeric repeats in a reaction catalyzed by its enzymatic component (TERT) [18] .
NSCs from different regions of the brain have different proliferative capacities and varying abilities to generate astrocytes, oligodendrocytes and neurons [19, 20] .
This may be reflected in the level of telomerase activity and telomere length reserve within cells from different neuro-anatomical compartments, in particular regions of high neurogenic activity such as the SVZ and SGZ [21] . Telomerase-mediated telomere homeostasis is therefore a likely key factor in brain plasticity throughout development and adulthood.
There is a suggestion here that a fuller understanding of the replicative histories of cells within tumour hierarchical compartments may provide clues as to the cancer cell of origin for a given brain neoplasm. Indeed telomerase activity has been detected in a growing number of brain tumours in the past decade [22] [23] [24] [25] [26] [27] . With preclinical and clinical advances in telomerase-therapeutics for cancer, there is anticipation that this will impact upon paediatric and adult tumours of the CNS.
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Brain tumourigenesis and tumour heterogeneity
A developmental relationship between tissue stem cells and cancer cells has been proposed over 50 years ago [28, 29] . However the pioneering demonstration of 'cancer stem cells' in human cancer was first made in leukaemia [30, 31] . From this initial discovery in hematopoietic tumours, evidence from most solid cancers studied defines restricted subsets of tumour cells that share characteristics of the corresponding normal tissue stem cells [32] [33] [34] [35] [36] . This paradigm includes prospective isolation of a minority population of brain tumour cells, based on the expression of the cell surface antigen CD133, known to be highly expressed in normal neural stem cells. These putative brain cancer stem cells were isolated from medulloblastoma, pilocytic astrocytoma, glioblastoma multiforme and anaplastic ependymoma and possessed a marked capacity for self-renewal (evidenced by the formation of floating aggregates termed tumourspheres), proliferation and differentiation [37] [38] [39] [40] .
Crucially, only the CD133+ fraction was capable of tumour initiation upon orthotopic transplantation into non-obese diabetic severe combined immunodeficient (NOD-SCID) mouse brain [41] . The CD133+ fraction produced a tumour that generated a phenocopy of the original tumour and could be serially transplanted into secondary recipients, providing evidence of self-renewal capacity in vivo (Singh 2004 
Developmental Neurobiology
Neuroepithelial cells, radial glia and early neurogenesis
The origin of all CNS cells can be traced to a single layer of embryological cells, which constitute the neuroepithelium. The edges of this sheet fold together to form the neural tube, which later gives rise to the ventricular system and spinal canal.
Initially, neuroepithelial cells divide symmetrically in order to increase the stem cell pool; thereafter these highly plastic cells proliferate and acquire regional identities in a spatial-temporal manner [10] . It is likely that neuroepithelial cells differentiate directly into radial glial cells in the embryonic ventricular zone [42] , although this has
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not been confirmed experimentally. Some recent supporting evidence is presented by the derivation of both neuroepithelial cells and radial glia from human embryonic stem cells; the course of differentiation (with respect to morphology change and lineage-specific marker expression) followed a temporal manner with neuroepithelial cells generated first, followed later by radial glial cells and finally mature neurons [43] .
The fate and function of a radial glial cell varies considerably from region to region in the CNS. It had long been accepted that radial glia are both astroglial progenitors [44, 45] and oligodendrocyte progenitors [46, 47] , but recent evidence has demonstrated that radial glia produce most of the cortical neurons [48] [49] [50] . Radial glial cells thus serve as neural stem/progenitor cells for the majority of neurogenesis and gliogenesis in the developing brain and gives rise to the astrocytic-like neural stem cells of the adult brain [48] [49] [50] [51] [52] . Whether radial glia transform directly into an adult multipotent neural stem cell or progenitor, or whether they first differentiate into an intermediate cell type, is unknown (see question marks, Figure 1 ). This concept of early neurogenesis is in dramatic contrast from the long-held view that embryonic, post-natal and adult NSCs are discrete unrelated populations.
Multipotent neural stem cells and neurogenesis in the mature CNS
Although widespread neurogenesis is restricted to the embryonic period, a limited number of neural stem cells persist throughout adulthood and are restricted mainly to two neurogenetic domains [13, 14, 53] . The largest of these regions is the mammalian SVZ situated throughout the lateral walls of the forebrain lateral ventricles [11] . A similar hierarchical neurogenetic system exists in the SGZ, an area corresponding to the dentate gyrus of the hippocampal granular layer [54, 55] . Stem
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cell progeny generated within these regions populate the growing CNS parenchyma, later differentiating into mature neuronal and glial fates, specified in a precise spatialtemporal manner [56] . Cells that express the intermediate filament astroglial marker, glial fibrillary acidic protein (GFAP), have been identified as putative adult neural stem cells in this region, also known as Type B cells [57, 58] (Figure 1 ). The embryonic origin of Type B cells has been confirmed using in vivo lineage tracing techniques and shows that adult subventricular cells are not related to embryonic subventricular precursors, but embryonic ventricular radial glia [59, 60] .
Further support of the astrocytic nature of NSCs has been confirmed in experiments in which GFAP+ cells were conditionally ablated in the brain of adult mouse, resulting in near complete loss of neurogenesis [61, 62] . Type B cells are proposed to be relatively quiescent with a cell cycle duration of ~24 hours and constitute a small fraction of the total astrocytic population in the SVZ [57] .
Pioneering experiments retrospectively viewed, adds support to this notion; Reynolds and Weiss in 1992, isolated a small population of cells (<0.1% of total cells) from the adult striatum that could proliferate and generate multiple clones of cells in freefloating clusters in vitro called neurospheres [63] . It is worth noting that even with current refined methods to isolate neural stem cells using the neurosphere assay, the stem cell content is variable; although Type B and Type C cells can produce neurospheres, not all cells within the neurosphere express stem cell markers [58, 64] . Type G granule neurons [65] . Over the course of development, NSCs not only feature altered morphology but also exhibit changes to gene expression profiles in a temporalspecific manner [66] . This expression profile may underlie an intrinsic developmental program as progenitors grown in culture generate progeny at certain times, similar to progenitors in vivo [67] . (Figure 1 ).
The role of telomeres and telomerase during neurogenesis
Most studies aimed at understanding the nature of NSCs with respect to selfrenewal, proliferation and differentiation, focus on external cues such as secreted growth factors [69, 70] . Few studies have addressed the role of intrinsic mechanisms regulating NSC behaviour [71] . Chromosome integrity is essential for cell viability, therefore highly proliferative cell types such as tissue stem cells, require active telomere maintenance strategies to proliferate indefinitely or at least long enough for the host organism to reach reproductive age. The role of telomere and telomerase dynamics in NSC compartments has scarcely been addressed. In the mouse, high levels of TERT and TERC (murine telomerase RNA subunit) mRNA are present in the developing neural tube as early as E10.5 [72] . Both telomerase subunits continue to be expressed in different regions of the developing murine CNS and correlates with
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the proliferation of neural progenitors [73] [74] [75] . This suggests a role for telomerase during specification of neural cell types. Consistent with our knowledge of neurogenetic regions of the adult brain, telomerase activity has been shown in neural precursor cells isolated from the SVZ and hippocampus in adult mice [21] . With reference to stem cell populations in other tissues, the current working hypothesis states that telomerase activity in NSCs (and actively proliferating early neural precursors) may combat induced telomere shortening upon mitotic division. However, human progenitor cells isolated from the developing cortex which exhibit low/absent levels of telomerase activity, undergo decreased neurogenesis and eventually enter replicative senescence in vitro [76] . These findings are corroborated by studies in other tissues where low levels of telomerase activity have been found in tissue stem cells such as haematopoietic, skin, intestinal crypt and pancreas [77] [78] [79] [80] . In all these cases, telomerase activity is insufficient to completely prevent telomere loss and senescence. Rather, telomerase in tissue stem cells may slow the rate of telomere shortening and maintain a replicative reserve pre-determined for the tissue stem cell in question. It is difficult to argue that this phenomenon is not a primitive tumoursuppressor mechanism and perhaps one that predates protein-mediated tumour suppression.
Telomere attrition dramatically impairs the in vitro proliferation of adult NSCs isolated from the SVZ of telomerase-deficient mice, but not that of embryonic NSCs, even though the latter exhibited critically shortened telomeres. This is consistent with a recent report describing telomerase levels as high in embryonic cortical neural progenitor cells, but low in newly generated neurons and mature neurons [81] . Collectively these results hint at intrinsic differences in the protective states between adult and embryonic NSCs, with respect to chromosomal stability and
response to dysfunctional telomeres [82] . A comprehensive understanding of how the regulation of telomeres/telomerase is tightly linked to cell cycle regulation in tissue stem cells will be crucial to determining how cancer may arise when stem cell regulation is perturbed. [84, 85] . Brain tumours in which telomerase activity has been detected include glioblastoma, anaplastic astrocytoma, oligodendroglioma, primitive neuro-ectodermal tumours, medulloblastoma and ependymoma [23] [24] [25] [26] . These data indicate that hTERT reactivation or overexpression is an essential event for tumour progression in CNS tumours. The role of hTERT may not be restricted to addition of telomere repeats as mouse TERT has been shown to promote cell survival (prevents apoptosis) in neurons, a function that does not require the telomerase RNA subunit [86] . This extracurricular TERT function may contribute to cancer development and aging independently of telomere lengthening and telomerase activity.
Cellular Immortality and Tumour Initiation
Telomeres and telomerase in brain tumours
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In a comprehensive analysis of telomere length, the majority of grade II astrocytomas, anaplastic astrocytomas and glioblastomas with telomerase activity, exhibited significantly shorter mean telomere lengths relative to corresponding tumours with undetectable telomerase activity and to normal brain tissue. Similarly, all primitive neuroectodermal tumours exhibited shorter telomere lengths relative to normal brain tissue [24] . Recent findings from our own laboratory reveal that paediatric glioblastoma multiforme and ependymoma, tumours of glial origin, have significantly longer mean telomere length than those of supratentorial neuroectodermal tumours and medulloblastoma, tumours of neuroectodermal origin.
This highlights the consideration required for telomere length with respect to duration/course of treatment when using anti-telomerase drugs which are predicted to exert their effects upon telomere shortening (Rahman R et al. unpublished data). The concurrent shortening of telomeres with telomerase reactivation/overexpression supports a hypothesis that telomerase is required to maintain both minimum length and a terminal capping structure at a subset of critically shortened telomeres [87] .
The perspective presented by the stem cell origin of brain tumours implies that the genetic alterations that lead to cancer, accumulate in NSCs rather than mature neural cells. As NSCs would already exhibit telomerase activity, one would predict the enzyme to be overexpressed rather than reactivated. Whether telomerase activity increases during later stages of carcinogenesis is unclear [88] . Similar to selfrenewing tissues where hTERT expression is insufficient to halt progressive telomere shortening, telomere shortening may continue within a proliferating transformed neural stem cell. However aberrant and sustained hTERT expression likely results in telomere stabilization both with respect to telomere length and 3' telomere capping structure ( Figure 2 ). Elucidation of telomerase levels and telomere length within
different neurogenetic subsets will influence strategies to target telomerase in brain cancer.
The Brain Tumour Stem Cell Paradigm
An acceptance of tumour hierarchical organisation readily leads to a developmental-centred view of tumourigenesis, where brain tumours represent aberrantly differentiated tissue, in turn reflecting dysregulated neurogenesis. The stem cell paradigm for brain tumours presents tumour-initiating events as occurring within the genome of a cellular entity with neural stem cell-like properties.
The identification of brain tumour stem cells was prospectively demonstrated
by Peter Dirks and colleagues using cells derived from glioblastoma and medulloblastoma. As few as 100 cells sorted positively for the cell surface antigen CD133, were capable of initiating infiltrative tumours upon orthotopic transplantation into SCID mice whereas injection of 100,000 CD133-cells failed to initiate tumours [41] . In a later study, tumour stem cells isolated from ependymoma manifested a radial glial phenotype with CD133+/Nestin+/RC2+/BLBP+ positivity confirmed to be tumourigenic [40] .
It is important to note that a definitive demonstration of tumour stem cells in the brain is lacking as CD133 enriches for, rather than definitively identifies, cancer stem cells. This caveat has been emphasized with recent studies showing that CD133-glioblastoma cells have tumour-initiating ability [89, 90] . In addition, it is the CD133+/Nestin+/RC2-/BLBP-phenotype that exhibited a tumourigenic phenotype in medulloblastoma in contrast to the CD133+/Nestin+/RC2+/BLBP+ phenotype in ependymoma [40] , suggesting the characteristics of these two subsets may reflect different cell of origins. Clearly stem-like properties in a tumour cell cannot be taken
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as direct evidence for neoplastic transformation occurring in a neural stem cell that originates in a zone of active neurogenesis. The cancer stem cell hypothesis and the cellular origin of cancer are distinct paradigms. It is conceivable that a neural progenitor or mature cell could give the appearance of 'stemness' upon neoplastic transformation ( Figure 2 ).
An alternative focus is that of molecular events that permit tumour initiation rather than on the cell type that initiated the tumour. The cancer stem cell hypothesis predicts mechanistic similarities between self-renewal of cancer stem cells and normal stem cells. In brain tumours there is particular interest in the Notch [91, 92] and Sonic-hedgehog [93, 94] pathways, as these have been shown to be important for normal stem cell self-renewal as well as dysregulated growth in cancer.
Overexpression of Notch receptors and their ligands Delta-like 1 (DLK1) and Jagged
(JAG1) correlates with the proliferative capacity of human glioma cells, implicating
Notch as a positive effector of self-renewal in adult neural stem cells [95] .
Furthermore, overexpression of Notch-2 intracellular domain protein increases proliferation of medulloblastoma cell lines [96] , whereas medulloblastoma growth is suppressed by the known Notch inhibitor, γ-secretase [97] . Similarly Sonic Hedgehog (SHH) and its downstream effectors, glioma-associated homologue 1 (GLI1), GLI2 and GLI3 have been shown to specifically regulate self-renewal and neurogenesis within the external granular layer of the post-natal cerebellum and to control proliferation of precursors within the adult SVZ [98] . Mutations in this pathway are thus implicated in the initiation of medulloblastoma [99, 100] .
Another emerging concept is that brain tumour stem cells may crucially be supported by a specific microenvironment which mimics the neural vascular niche Since telomerase activity has been detected in almost all advanced brain tumours, the use of telomerase inhibitors may provide an attractive approach to therapy. These may be most effective in reducing the risk of relapse by targeting cancer stem cells. As normal neural stem cells would be expected to have longer telomeres than brain cancer stem cells, it follows that telomere depletion will be spared in the normal stem cell pool [103, 104] . There is a practical consideration here with respect to telomere length: if anti-telomerase approaches rely on telomere 
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mutational events drive progression of the tumour. As the transformed neural stem cell (aberrantly) differentiates, telomere shortening is likely to occur; however due to hTERT acting on critically shortened telomeres, telomere length in the (mature) malignant neural cell would be expected to be stabilized. Although depicted here as arising in a neural stem cell, it remains plausible that the tumour cell of origin is a neural progenitor; in the latter scenario, the progenitor cell may acquire the capacity to self-renew through mutation, increasing the propensity to initiate a tumour. 
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